| scholarly article | Q13442814 |
| P50 | author | Toshinori Nakayama | Q37834721 |
| Masaru Taniguchi | Q106908160 | ||
| P2093 | author name string | Kanako Shimizu | |
| Yoshitaka Okamoto | |||
| Shinichiro Motohashi | |||
| Shin-Ichiro Fujii | |||
| Naoki Kunii | |||
| P2860 | cites work | CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor | Q27646101 |
| Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove | Q27740401 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 | ||
| Generation of germline-competent induced pluripotent stem cells | Q28131699 | ||
| Revisions in the International System for Staging Lung Cancer | Q28241070 | ||
| CD1: antigen presentation and T cell function | Q28251508 | ||
| CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides | Q28254991 | ||
| The biology of NKT cells | Q28277482 | ||
| Homogenous junctional sequence of the V14+ T-cell antigen receptor alpha chain expanded in unprimed mice | Q33679095 | ||
| Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review | Q34071781 | ||
| Cytokine patterns in patients with cancer: a systematic review. | Q34342581 | ||
| Positive selection of invariant V alpha 14+ T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells | Q34703733 | ||
| The regulatory role of Valpha14 NKT cells in innate and acquired immune response. | Q35051569 | ||
| The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer | Q35196990 | ||
| Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein | Q36371349 | ||
| The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation | Q36402640 | ||
| CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution | Q36404242 | ||
| CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells | Q36404272 | ||
| Clinical applications of natural killer T cell-based immunotherapy for cancer | Q37092313 | ||
| Sequence and expression of transcripts of the T-cell antigen receptor alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma | Q37407846 | ||
| Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer | Q37846981 | ||
| Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction | Q39158363 | ||
| NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells | Q40618321 | ||
| Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells | Q40734937 | ||
| Murine CD1d-restricted T cell recognition of cellular lipids | Q40894441 | ||
| Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells | Q42130104 | ||
| Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. | Q42803970 | ||
| NKT cells: what's in a name? | Q47895830 | ||
| A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. | Q51833179 | ||
| Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. | Q52023804 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 | ||
| Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide | Q60489559 | ||
| Predominant use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin | Q69366242 | ||
| Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells | Q73098737 | ||
| Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors | Q73889862 | ||
| A novel recognition motif of human NKT antigen receptor for a glycolipid ligand | Q77849962 | ||
| Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide | Q78145103 | ||
| Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients | Q78387479 | ||
| A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer | Q79209407 | ||
| The NKT cell system: bridging innate and acquired immunity | Q79324707 | ||
| A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer | Q81498372 | ||
| Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide | Q81757958 | ||
| Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy | Q83032142 | ||
| Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells | Q83995222 | ||
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 409 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | NKT cells as an ideal anti-tumor immunotherapeutic | |
| P478 | volume | 4 |
| Q36467378 | 2015 Guidance on cancer immunotherapy development in early-phase clinical studies |
| Q35641721 | Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. |
| Q89360097 | All work and no Id2 makes a dull NKT cell |
| Q44851304 | Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses |
| Q38764629 | Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses. |
| Q26778648 | Antitumor Responses of Invariant Natural Killer T Cells |
| Q98906904 | Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis |
| Q36016694 | Chronic alcohol consumption inhibits melanoma growth but decreases the survival of mice immunized with tumor cell lysate and boosted with α-galactosylceramide |
| Q37689104 | Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer |
| Q42556477 | Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells |
| Q48326911 | Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals. |
| Q50498502 | Efficient Regeneration of Human Vα24+ Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo. |
| Q91756406 | Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α-Gal epitopes |
| Q41139823 | Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy |
| Q37618482 | Escape from IFN-γ-dependent immunosurveillance in tumorigenesis. |
| Q47193039 | Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine |
| Q50739432 | Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples. |
| Q41174284 | Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells |
| Q38410637 | From the Deep Sea to Everywhere: Environmental Antigens for iNKT Cells |
| Q38456346 | Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer |
| Q38885794 | Glycolipid activators of invariant NKT cells as vaccine adjuvants |
| Q64071651 | Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy |
| Q46350666 | Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy. |
| Q38890717 | Immunotherapeutic strategies targeting natural killer T cell responses in cancer. |
| Q26750617 | Immunotherapy for lung cancer: advances and prospects |
| Q40507213 | In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus |
| Q38214635 | Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy |
| Q48316500 | Innate immune cells for immunotherapy of autoimmune and cancer disorders. |
| Q47549568 | Integration of oncogenes via Sleeping Beauty as a mouse model of HPV16+ Oral tumor and immunologic control |
| Q49428366 | Intracellular IL-4 and IFN-γ expression in iNKT cells from patients with chronic lymphocytic leukemia |
| Q36746282 | Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. |
| Q49898897 | Invariant NKT cells promote skin wound healing by preventing a prolonged neutrophilic inflammatory response |
| Q35085309 | Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. |
| Q38725344 | Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling |
| Q38590013 | Lipid and small-molecule display by CD1 and MR1. |
| Q26866223 | NKT cell networks in the regulation of tumor immunity |
| Q42368030 | Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity |
| Q47221129 | Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective |
| Q35506478 | Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice |
| Q28085038 | Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis |
| Q51828144 | Natural killer T cells: drivers or passengers in preventing human disease? |
| Q37721209 | Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases |
| Q57300020 | Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression |
| Q33720359 | Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential |
| Q64236633 | Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation |
| Q38266198 | T-cell-associated cellular immunotherapy for lung cancer |
| Q38990873 | The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia. |
| Q35600087 | The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products |
| Q38611633 | The burgeoning family of unconventional T cells |
| Q89074520 | The interaction between invariant Natural Killer T cells and the mucosal microbiota |
| Q58777562 | Tissue-Specific Roles of NKT Cells in Tumor Immunity |
| Q63362826 | Tissue-specific functions of invariant natural killer T cells |
| Q37086432 | Transcription factor Bcl11b sustains iNKT1 and iNKT2 cell programs, restricts iNKT17 cell program, and governs iNKT cell survival |
| Q36866484 | Tumor suppression in mice lacking GABARAP, an Atg8/LC3 family member implicated in autophagy, is associated with alterations in cytokine secretion and cell death. |
| Q42258167 | Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. |
| Q93062542 | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| Q41759021 | α-Galactosylceramide stimulates splenic lymphocyte proliferation in vitro and increases antibody production in vivo in late neonatal-age mice |
Search more.